PNC-27 Research Guide — p53/Penetratin Chimeric Peptide, HDM-2 Membrane Targeting & Selective Cancer Cell Pore Formation (2026)
- PNC-27 is a synthetic 32-residue chimeric anticancer peptide developed by Matthew R. Pincus, Josef Michl, and Wilbur B. Bowne (SUNY Downstate/Mount Sinai group). It consists of two covalently linked functional domains: (1) p53 residues 12–26, corresponding to the HDM-2-binding domain of the p53 tumor suppressor protein; and (2) a C-terminal penetratin/membrane residency peptide (MRP) leader sequence derived from the Antennapedia homeodomain. Both domains must be covalently linked — either domain alone, or both used separately, does not produce the selective cancer cell killing effect. YPB offers research-grade PNC-27 (Research Use Only).
- Mechanism: HDM-2 (human double minute 2; also MDM-2) is aberrantly expressed on the plasma membrane of transformed/cancer cells but not on untransformed normal cells. PNC-27 exploits this differential plasma membrane HDM-2 expression: it binds to membrane-localized HDM-2 on cancer cell surfaces via its p53 12–26 domain, and the penetratin/MRP domain anchors the peptide-HDM-2 complex in the membrane. The amphipathic alpha-helical conformation adopted by PNC-27 when HDM-2-bound then enables oligomerization and transmembrane pore formation. The resulting pores cause rapid cancer cell lysis through necrosis (not apoptosis). This mechanism has been termed “poptosis” by the Pincus group (2024, Biomedicines).
- Selectivity basis: The selectivity for cancer cells over normal cells depends entirely on the differential plasma membrane expression of HDM-2. In untransformed cells, HDM-2 is predominantly nuclear (not membrane-expressed); PNC-27 enters normal cells, is cleaved, and only the p53 domain reaches the nucleus — no membrane pore formation occurs. Cancer cells overexpress HDM-2 on their plasma membranes, presenting the binding target that retains PNC-27 at the membrane for pore formation.
- Published evidence: Sarafraz-Yazdi et al. (2010) PNAS (PMID: 20080680) — landmark structural and functional characterization; confirmed HDM-2 plasma membrane expression in cancer cells; pore formation by electron microscopy. Tested in pancreatic cancer, ovarian cancer, leukemia, and multiple other cancer cell lines; ex vivo research subjects-derived tumor data. No published clinical trial as of April 2026. Research Use Only (RUO). Updated April 2026.
What Is PNC-27 and Why Is Its Mechanism Unique Among Anticancer Research Peptides?
HDM-2 Plasma Membrane Targeting
“Poptosis” — Pore-Mediated Necrosis
PNC-27 occupies a genuinely unique position in anticancer research peptide biology: it kills cancer cells not by blocking a receptor, not by inducing classical apoptosis through intracellular signaling, and not by inhibiting a protein-protein interaction. It kills them by forming physical pores in the cancer cell plasma membrane, causing rapid lysis through a mechanism that is entirely independent of intracellular signal transduction pathways, p53 tumor suppressor status, or any other downstream cancer biology variable. Updated April 2026. Most compound with research interest ins require specific intracellular targets to be present, functional, or mutated in a particular way; PNC-27’s activity depends on a single extracellular criterion: whether HDM-2 protein is present on the cancer cell’s plasma membrane surface.
This mechanism — designated “poptosis” (peptide-induced transmembrane pore formation) by the Pincus group in a 2024 Biomedicines review — is conceptually novel because the selectivity target (membrane HDM-2 expression) is a cancer-specific surface property rather than an intracellular target. The research tool value of PNC-27 is therefore as a probe for membrane HDM-2 expression in cancer cell biology and as a reference compound for the poptosis mechanism class of anticancer peptides.
Key Characteristics
| Parameter | Value |
|---|---|
| Structure | 32-residue chimeric peptide: [p53 residues 12–26 (HDM-2 binding domain)] + [penetratin/MRP C-terminal leader sequence]. Both domains must be covalently linked for activity. |
| Domain 1: p53 12–26 | Corresponds to the transactivation domain of p53 that normally binds MDM-2/HDM-2 intracellularly; in PNC-27, this domain binds membrane-expressed HDM-2 on cancer cell surfaces |
| Domain 2: Penetratin/MRP | Derived from Antennapedia homeodomain; membrane-inserting/cell-penetrating peptide (CPP) sequence; anchors the PNC-27/HDM-2 complex in the cancer cell plasma membrane; enables amphipathic alpha-helical pore formation |
| Mechanism | Binds membrane-HDM-2 on cancer cell surface → adopts amphipathic alpha-helical conformation → oligomerizes in membrane → transmembrane pore formation (“poptosis”) → rapid cancer cell necrosis (cytoplasmic contents released; lysis) |
| Cell Death Modality | Necrosis (not apoptosis); transmembrane pore formation is cytoplasm-flooding and immediate; independent of caspase cascades, p53 status, Bcl-2 family, or any specific intracellular signaling pathway |
| Selectivity Target | Plasma membrane HDM-2 expression: present on transformed/cancer cells; absent on plasma membrane of untransformed normal cells (HDM-2 is nuclear in normal cells) |
| Landmark Publication | Sarafraz-Yazdi et al. (2010) PNAS 107(5):1918–1923. PMID: 20080680. Also: Sarafraz-Yazdi et al. (2022) Biomedicines PMC9138867. |
| Cancer Cell Lines Tested | Pancreatic (PANC-1, MiaPaCa-2); ovarian; leukemia (HL-60, U937); breast; and primary human tumor ex vivo specimens. Normal cell types spared in all published studies. |
| Half-Life | Not extensively characterized; moderate stability expected for 32-AA peptide with penetratin sequence; primarily a research tool for cell-based assays |
| FDA Status | Not research-grade; no clinical trials published as of April 2026. Research Use Only (RUO). |
| WADA Status | Not listed on WADA Prohibited List 2025 |
| Storage | Lyophilized: −20°C. Reconstituted in sterile water or PBS; 2–8°C, use within 14 days. Avoid repeated freeze-thaw cycles. |
How Does PNC-27 Work? Membrane HDM-2 Targeting and Poptosis
The HDM-2 Membrane Localization Discovery
The mechanism of PNC-27 depends on a cancer biology finding that was itself a significant discovery: HDM-2 (the human ortholog of MDM-2), classically known as a nuclear E3 ubiquitin ligase that targets p53 for proteasomal degradation, is expressed on the plasma membrane of transformed/cancer cells but not on the surface of untransformed normal cells. This membrane expression of HDM-2 appears to be a cancer-specific phenotype arising from the dysregulation of HDM-2 expression and trafficking that is ubiquitous in transformed cells. The Pincus group confirmed plasma membrane HDM-2 expression by immunolocalization in multiple cancer cell lines and by immunoscanning electron microscopy (immuno-SEM) showing HDM-2 gold-particle decoration on cancer cell surfaces but not on normal cell surfaces.
PNC-27 Binding, Helix Formation, and Pore Assembly
When PNC-27 encounters a cancer cell, its p53 12–26 domain binds to surface-expressed HDM-2 in a conformation that is directly superimposable on the known 3D structure of p53 residues 12–26 when bound to HDM-2 (confirmed by NMR; Rosal et al. 2004; Biochemistry). The C-terminal penetratin/MRP sequence anchors the peptide-HDM-2 complex in the plasma membrane. Once membrane-associated, PNC-27 adopts a strongly amphipathic alpha-helix-loop-alpha-helix conformation that is membrane-active. Multiple PNC-27 molecules oligomerize around the HDM-2 binding sites in the cancer cell membrane, forming annular transmembrane pores that allow cytoplasmic contents to flow out. Transmission electron microscopy (TEM) confirmed pore formation by visualization of membrane disruption in PNC-27-treated cancer cells. The resulting lysis is rapid, occurring within minutes to hours of peptide exposure at effective concentrations.
What Research Applications Has PNC-27 Been Studied For?
Cancer Cell Biology and HDM-2 Membrane Expression Research
The primary research application of PNC-27 is as a probe for HDM-2 plasma membrane expression in transformed cells. It allows researchers to directly assess which cancer cell lines express HDM-2 on their plasma membranes (as opposed to only intranuclearly) by using PNC-27 cytotoxicity as a functional readout: cells that express membrane HDM-2 are killed; cells that do not are spared. This functional selectivity assay is complementary to immunostaining and flow cytometry for membrane HDM-2 expression assessment.
Pancreatic Cancer Research
Published data from the Pincus/Bowne group (Ann Surg Oncol, 2008) demonstrated that PNC-27 induces tumor necrosis rather than apoptosis in human pancreatic cancer cells (PANC-1, MiaPaCa-2). Pancreatic cancer is particularly relevant because it is one of the cancers with highest HDM-2 overexpression and membrane localization, making it among the cell types most responsive to PNC-27 in published studies.
Ovarian Cancer Research
Sarafraz-Yazdi et al. (2015, Ann Clin Lab Sci) published ex vivo data from research subjects-derived epithelial ovarian cancer specimens treated with PNC-27, demonstrating cancer cell killing in primary tumor cells from research subjectss while normal cells in the specimens were spared. This research subjects-derived ex vivo evidence is among the strongest evidence for clinical relevance of the poptosis mechanism.
Hematological Malignancy Research
PNC-27 was tested in leukemia cell lines (HL-60, U937, poorly differentiated leukemia lines) with documented HDM-2 membrane expression, demonstrating selective necrosis of leukemia cells. This expanded the mechanism beyond solid tumors to non-solid tissue malignancies, with normal hematopoietic cells spared.
What Does the Research Data Show?
| Study / Context | Model | Key Finding & Notes | Year |
|---|---|---|---|
| Sarafraz-Yazdi et al. — PNAS landmark | In vitro (multiple cancer cell lines) + structural (NMR, immuno-SEM) | PNC-27 binds membrane HDM-2 in p53-like conformation; confirmed by NMR superimposition; immuno-SEM showed gold-particle HDM-2 labeling on cancer cell surfaces; TEM confirmed pore formation; selective cancer cell necrosis vs. normal cell sparing; covalent linkage required. (PNAS, 2010, PMID: 20080680) | 2010 |
| Pancreatic cancer — Ann Surg Oncol | In vitro (PANC-1, MiaPaCa-2 human pancreatic cancer cells) | PNC-27 induces tumor cell necrosis (not apoptosis) in pancreatic cancer cells; penetratin sequence required for membrane pore formation; normal cells spared. Consistent with poptosis mechanism. (Bowne et al. 2008, PMID: 18931881) | 2008 |
| Ovarian cancer — research subjects-derived ex vivo | Ex vivo (primary human epithelial ovarian cancer specimens) | PNC-27 selectively lysed cancer cells in research subjects-derived ovarian tumor specimens; normal cells in the same specimens spared. Most clinically relevant evidence published for PNC-27 mechanism. (Sarafraz-Yazdi et al. 2015) | 2015 |
| Leukemia cell lines | In vitro (HL-60, U937, poorly differentiated leukemia) | PNC-27 induced necrosis in leukemia cells with confirmed membrane HDM-2 expression; normal hematopoietic cells spared. Extended PNC-27 activity from solid to non-solid tumors. (Davitt et al. 2014) | 2014 |
| Clinical trial | No published trial as of April 2026 | No published Phase 1 or Phase 2 human clinical trial for PNC-27 as of April 2026. All activity data from in vitro and ex vivo models. In vivo pharmacokinetics, systemic tolerability, and clinical efficacy in human subjects are not established. | N/A |
How Does PNC-27 Compare to Other Cancer Biology Research Peptides?
| Parameter | PNC-27 | FOXO4-DRI | LL-37 | KPV |
|---|---|---|---|---|
| Primary Target Cell | Cancer cells (transformed): HDM-2 plasma membrane expression required for activity | Senescent cells: FOXO4–p53 axis upregulated; selective apoptosis via p53 mitochondrial translocation | Bacteria + cancer cells: AMP-based membrane disruption; direct antimicrobial + immunomodulatory | Primarily anti-inflammatory, gut epithelial barrier; not cancer-selective |
| Selectivity Mechanism | Differential plasma membrane HDM-2 expression: present on cancer, absent on normal cells | Differential FOXO4 expression: elevated in senescent cells, not normal cells | Selectivity via charge: negative charge of cancer/bacterial membranes vs. normal cell membranes | MC1R/MC3R receptor expression in inflamed epithelial tissue |
| Cell Death Mode | Necrosis (poptosis): transmembrane pore formation → cytoplasmic lysis; rapid; p53-independent | Apoptosis: intrinsic pathway via p53 mitochondrial translocation; caspase-dependent | Rapid necrosis via membrane disruption (antimicrobial); varies by cell context | No cytotoxic activity; anti-inflammatory |
| p53 Pathway Involvement | Uses p53 12–26 domain for HDM-2 binding; cell death is p53-independent (pore mechanism does not require functional p53) | Releases p53 from FOXO4 sequestration; requires functional p53 for mitochondrial apoptosis | No p53 pathway involvement | No p53 pathway involvement |
| Published Human Data | Ex vivo research subjects-derived ovarian and pancreatic cancer specimens; no published clinical trial | Mouse models only; no human clinical trial | Preclinical and observational; no research-grade indication specifically for LL-37 | Preclinical; no published large RCT |
| YPB Position | YPB catalog (RUO) — see product | YPB.255 — see guide | YPB.271 — see guide | YPB catalog — see guide |
PNC-27 and FOXO4-DRI are the two cell-type-selective cytotoxic peptides in the YPB catalog, but they operate through completely different mechanisms. FOXO4-DRI targets the senescent cell-specific FOXO4–p53 survival axis (see the FOXO4-DRI Research Guide) and induces apoptosis; PNC-27 targets cancer cell-specific membrane HDM-2 expression and induces necrosis by pore formation. Both are cellular selectivity tools based on surface marker expression rather than intracellular pathway targeting, and both are useful for researching their respective selective-cytotoxicity mechanisms. LL-37 (see the LL-37 Research Guide) also has cancer cell membrane disruption activity but through a charge-based AMP mechanism rather than HDM-2 targeting.
What Should Researchers Know About PNC-27 Handling and Verification?
Chimeric Structure Integrity
The fundamental research requirement for PNC-27 experiments is that the chimeric single-peptide structure (p53 12–26 + penetratin/MRP; both domains covalently linked) is confirmed intact in the research batch. The experimental evidence established that neither domain alone nor both used separately produces cancer cell killing. Fragmentation or incomplete synthesis that produces the two domains as separate entities would yield inactive material despite passing bulk purity criteria. Full-length 32-residue confirmation by MS and reversed-phase HPLC (single peak at the correct retention time; no shorter fragment co-eluting peaks) is the critical quality parameter.
Activity Assay Recommendation
For critical research applications, a cell-based activity assay confirming selective cancer cell killing (e.g., confirmed cytotoxicity in a documented HDM-2-expressing cancer cell line such as PANC-1 at expected IC50, with confirmed sparing of a matched normal cell control) is the most rigorous quality confirmation. HPLC purity and MS mass alone confirm chemical identity but not functional membrane-active conformation.
Storage
Lyophilized: −20°C for up to 24 months. Reconstituted in PBS or sterile water; 2–8°C, use within 14 days. Avoid repeated freeze-thaw cycles, which can cause aggregation of the amphipathic helix domains. All YPB PNC-27 batches include lot-traceable COA documentation through the COA Library.
Key Research Findings
- Novel mechanism “poptosis”: Peptide-induced transmembrane pore formation in cancer cell plasma membranes → rapid necrosis; independent of intracellular signal transduction, p53 status, caspases, Bcl-2 family, or any specific intracellular pathway.
- Selectivity target: membrane HDM-2 expression: HDM-2 aberrantly expressed on cancer cell plasma membranes; absent from plasma membrane of untransformed normal cells. PNC-27 binds only where membrane HDM-2 is present; normal cell sparing confirmed in all published studies.
- Covalent linkage required: p53 12–26 domain alone, penetratin/MRP alone, and both used separately — none produce selective cancer cell killing. Only covalently linked chimeric single peptide is active. Full-length integrity is the critical quality parameter.
- PNAS 2010 landmark (PMID: 20080680): NMR confirmation that PNC-27 p53 domain adopts HDM-2-binding conformation; immuno-SEM confirmed plasma membrane HDM-2 in cancer cells; TEM confirmed pore formation; structural and functional characterization complete.
- Ex vivo research subjects-derived efficacy: Primary human ovarian and pancreatic cancer specimens treated ex vivo; selective cancer cell necrosis confirmed in research subjects tissue. Among the strongest evidence for clinical relevance of the poptosis mechanism.
- p53-independent killing: PNC-27 kills cancer cells regardless of their p53 mutational status; because the mechanism is pore formation (not p53-dependent apoptosis), p53 function in the cancer cell is irrelevant.
- Necrosis, not apoptosis: The cell death mode is necrosis (rapid cytoplasmic lysis); this is mechanistically distinct from FOXO4-DRI (intrinsic apoptosis) or conventional chemotherapy (apoptosis induction).
- No published clinical trial (April 2026): All efficacy data in vitro and ex vivo; in vivo pharmacokinetics, systemic tolerability, and dose-response in intact animal models require further characterization for clinical translation.
Browse the Full Research Catalog
Market Demand and Research Interest
| Demand Indicator | PNC-27 Data Point |
|---|---|
| Research context | Cancer cell biology; HDM-2 membrane expression; p53/MDM-2 axis; anticancer peptides; selective cytotoxicity mechanisms; poptosis mechanism class |
| Landmark publication | Sarafraz-Yazdi et al. (2010) PNAS 107(5):1918–1923 (PMID: 20080680) — peer-reviewed characterization in one of the most prestigious biology journals |
| Unique mechanism | Only membrane-HDM-2-targeting pore-forming peptide in YPB catalog; only “poptosis” mechanism compound; only cancer-cell-selective necrosis tool |
| Research significance | p53-independent killing mechanism (active in p53-mutated cancers); mechanism entirely distinct from all conventional chemotherapies; relevant to compound resistance research |
| Pancreatic/ovarian cancer context | Two cancer types with very high unmet need and among the strongest published PNC-27 data; active research communities |
| Keyword difficulty range | Very low (KD <5); specialized cancer biology audience |
How Can Researchers Offer PNC-27 Under Their Own Brand?
Wholesale Pricing & Margin Analysis
| SKU | Compound | Premier ($497/mo) | Core ($297/mo) | Suggested MSRP | Premier Margin |
|---|---|---|---|---|---|
| YPB Catalog (RUO) | PNC-27 (p53/Penetratin Chimeric Anticancer Peptide) | TBC Premier | TBC Core | TBC | TBC at Premier tier |
Contact the YPB team for confirmed SKU, configuration, Premier and Core tier pricing. Use the YPB Profit Calculator to model projected revenue. White-label brands offering PNC-27 alongside FOXO4-DRI create the only white-label catalog covering two mechanistically distinct selective cytotoxic research peptides: PNC-27 (cancer cell-selective membrane pore necrosis via HDM-2) and FOXO4-DRI (senescent cell-selective mitochondrial apoptosis via FOXO4–p53). Download the full catalog for all cancer biology category pricing.
Methodology & Data Sources
Methodology & Data Sources
Scientific literature: PubMed searched for “PNC-27,” “p53 penetratin chimeric peptide,” “membrane HDM-2 cancer,” and “poptosis peptide.” Search conducted through April 2026.
Key sources: Sarafraz-Yazdi et al. (2010) PNAS (PMID: 20080680); Sarafraz-Yazdi et al. (2022) Biomedicines (PMC9138867); Bowne et al. (2008) Ann Surg Oncol (PMID: 18931881); Davitt et al. (2014, leukemia); Sarafraz-Yazdi et al. (2015, ovarian); Pincus et al. (2024) Biomedicines “poptosis” review (PMID: 38927351).
Limitations: All published PNC-27 data is from in vitro cell lines and ex vivo research subjects-derived specimens; no in vivo animal model or human clinical trial published as of April 2026. The research evidence base is primarily from the Pincus/Bowne/Michl/Sarafraz-Yazdi group; independent replication by other groups is limited. Mechanism is based on the novel “plasma membrane HDM-2 expression in cancer cells” hypothesis which, while supported by multiple published studies from the same group, warrants independent verification at scale. This article is for educational purposes only.
References
- Sarafraz-Yazdi, E., Bowne, W. B., Adler, V., Sookraj, K. A., Wu, V., Shteyler, V., Patel, H., Oxbury, W., Brandt-Rauf, P., Zenilman, M. E., Michl, J., & Pincus, M. R. (2010). Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes. Proc Natl Acad Sci USA, 107(5), 1918–1923. PMID: 20080680
- Sarafraz-Yazdi, E., Mumin, S., Cheung, D., Fridman, D., Lin, B., Wong, L., Rosal, R., Rudolph, R., Frenkel, M., Thadi, A., Morano, W. F., Bowne, W. B., Pincus, M. R., & Michl, J. (2022). PNC-27, a chimeric p53-penetratin peptide binds to HDM-2 in a p53 peptide-like structure, induces selective membrane-pore formation and leads to cancer cell lysis. Biomedicines, 10(5), 945. PMC9138867
- Bowne, W. B., Sookraj, K. A., Vishnevetsky, M., Adler, V., Yadzi, E., Lou, S., Koenke, J., Shteyler, V., Ikram, K., Harding, M., et al. (2008). The penetratin sequence in the anti-cancer PNC-28 peptide causes tumor necrosis rather than apoptosis of human pancreatic cancer cells. Ann Surg Oncol, 15(12), 3588–3600. PMID: 18931881
- Sarafraz-Yazdi, E., Gorelick, C., Wagreich, A. R., Salame, G., Angert, M., Gartman, C. H., Gupta, V., Bowne, W. B., Lee, Y. C., Abulafia, O., et al. (2015). Ex vivo efficacy of compound with research interest in PNC-27 in the treatment of research subjects-derived epithelial ovarian cancer. Ann Clin Lab Sci, 45(6), 650–658.
- Davitt, K., Babcock, B. D., Fenelus, M., Poon, C. K., Sarkar, A., Trivigno, V., Zolkind, P. A., Matthew, S. M., Grin’kina, N., Orynbayeva, Z., Shaikh, M. F., Adler, V., Michl, J., Sarafraz-Yazdi, E., Pincus, M. R., & Bowne, W. B. (2014). The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line. Ann Clin Lab Sci, 44(3), 241–248.
- Pincus, M. R., Silberstein, M., Zohar, N., Sarafraz-Yazdi, E., & Bowne, W. B. (2024). Poptosis or peptide-induced transmembrane pore formation: a novel way to kill cancer cells without affecting normal cells. Biomedicines, 12(6), 1144. PMID: 38927351. (Poptosis mechanism review.)
- Rosal, R., Pincus, M. R., Brandt-Rauf, P. W., Fine, R. L., Bhatta, R. S., & Bhatt, R. S. (2004). NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells. Biochemistry, 43(8), 1854–1861. (NMR structural basis for HDM-2 binding.)
- Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274(5289), 948–953. (MDM2/p53 structural context.)
- Joerger, A. C., & Fersht, A. R. (2008). Structural biology of the tumor suppressor p53. Annu Rev Biochem, 77, 557–592. (p53/MDM-2 axis biological context.)
Frequently Asked Questions
PNC-27 is a synthetic 32-residue chimeric anticancer peptide consisting of two covalently linked domains: p53 residues 12–26 (HDM-2/MDM-2 binding domain) + a C-terminal penetratin/MRP leader sequence. In research models, PNC-27 selectively kills cancer cells (but not untransformed normal cells) through a membrane pore formation mechanism termed “poptosis.” Mechanism: HDM-2 is aberrantly expressed on the plasma membrane of cancer/transformed cells (not on normal cell plasma membranes) → PNC-27 p53 domain binds membrane HDM-2 in the HDM-2-binding conformation → penetratin domain anchors complex in membrane → amphipathic alpha-helix promotes PNC-27 oligomerization → transmembrane pores form → rapid cancer cell necrosis (not apoptosis; p53-independent; intracellular pathway-independent). Selectivity confirmed by sparing of normal cells in all published studies. Landmark publication: Sarafraz-Yazdi et al. (2010) PNAS (PMID: 20080680). Ex vivo research subjects-derived ovarian and pancreatic cancer data published. No clinical trial as of April 2026. Research Use Only (RUO). Updated April 2026.
The selectivity depends entirely on the differential plasma membrane localization of HDM-2. In cancer/transformed cells, HDM-2 is overexpressed and a fraction of it is aberrantly trafficked to the plasma membrane, where it is accessible to extracellular PNC-27 binding. When PNC-27 binds to surface HDM-2, the penetratin/MRP domain anchors the complex in the membrane, enabling pore formation and necrosis. In untransformed normal cells, HDM-2 is expressed predominantly in the nucleus (its classical location as p53’s negative regulator) rather than at the plasma membrane. Without surface HDM-2 to bind and retain PNC-27 at the membrane, PNC-27 is not anchored in the plasma membrane of normal cells — instead, it enters the cell and is cleaved intracellularly; only the p53 domain reaches the nucleus, and no transmembrane pore forms. The Pincus group confirmed this mechanistically by showing that in normal cells treated with fluorescence-labeled PNC-27, only the N-terminal (p53) domain is detected in the nucleus, while the C-terminal (penetratin) domain is absent, indicating proteolytic cleavage inside the cell before membrane pore formation can occur.
Poptosis (peptide-induced transmembrane pore formation; coined by Pincus et al. in 2024 Biomedicines, PMID: 38927351) is a form of programmed cell lysis that is mechanistically distinct from apoptosis. Apoptosis is a tightly regulated, energy-dependent intracellular program: cells activate caspase cascades, fragment DNA, form apoptotic bodies, and die in an organized manner that does not trigger inflammation. Poptosis is a physical disruption: PNC-27 molecules form oligomeric transmembrane pores in the cancer cell plasma membrane, physically breaching the membrane barrier and allowing cytoplasmic contents to flow out. The result is rapid, osmotic, inflammatory necrosis — quite different from clean, quiet apoptosis. The research significance of this distinction: (1) poptosis does not require functional apoptotic machinery; cells with anti-apoptotic Bcl-2 overexpression, caspase deficiency, or p53 mutation (the most common resistance mechanisms to conventional chemotherapy) are still susceptible to poptosis if they express membrane HDM-2; (2) poptosis is rapid (minutes to hours) vs. apoptosis (hours to days); (3) the necrotic release of intracellular contents may potentially trigger immune responses against tumor antigens, which is an active research question in immuno-oncology.
The covalent linkage requirement reflects the two-step mechanism: the p53 12–26 domain must first anchor the peptide to membrane-expressed HDM-2 on the cancer cell surface, and immediately thereafter the penetratin/MRP domain must be physically present at the same membrane location to insert into the lipid bilayer and initiate pore formation. If the domains are used as separate peptides, even in a 1:1 mixture, the p53 domain can bind HDM-2 without the penetratin domain present at the membrane binding site; by the time the penetratin domain diffuses to the same membrane location, the spatial and temporal conditions for cooperated pore formation are not maintained. Published evidence: used p53 12–26 alone produced no cell killing; penetratin sequence alone produced no selective cancer cell killing; and both peptides together (separately, not linked) produced no selective killing. Only the single covalently linked 32-residue chimera produced selective cancer cell necrosis. This means that for research use, verification that the chimeric 32-residue structure is intact (not cleaved into its two component domains) is the most critical quality parameter for the batch.
Both PNC-27 and FOXO4-DRI are selective cytotoxic peptides based on surface/molecular markers specific to their target cell populations, but they have completely non-overlapping targets, mechanisms, and cell death modalities. PNC-27 targets cancer/transformed cells exclusively, exploiting their aberrant plasma membrane HDM-2 expression. It kills by transmembrane pore formation (poptosis; necrosis; minutes to hours; p53-independent; intracellular pathway-independent). FOXO4-DRI targets senescent cells exclusively, exploiting their elevated FOXO4 expression and the FOXO4–p53 nuclear survival complex. It kills by intrinsic mitochondrial apoptosis after disrupting the FOXO4–p53 survival axis (requires functional p53 in the target cells; caspase-dependent; hours to days). From a catalog perspective: PNC-27 is the cancer cell-selective membrane pore research tool; FOXO4-DRI is the senescent cell-selective apoptosis research tool. They address different research questions about selective cytotoxicity for different cell populations and could be used in the same aging+cancer research program studying two distinct aberrant cell populations.
Yes. YourPeptideBrand.com provides white-label dropship for PNC-27 (Research Use Only). White-label storefronts include pre-built RUO-compliant product pages with poptosis mechanism descriptions, membrane HDM-2 selectivity context, published cancer cell data (PANC-1, ovarian, leukemia; clearly framed as in vitro/ex vivo research), and COA library links. Contact the YPB team for confirmed SKU, configuration, Premier and Core pricing, and use the profit calculator to model projected revenue.
Every PNC-27 batch includes a lot-specific COA: HPLC purity (≥98%; single peak confirming intact 32-residue chimeric structure; any shorter peptide fragment co-eluting peaks would indicate incomplete synthesis or degradation), MS confirmation at the correct 32-residue molecular weight (confirming both domains are present in the intact chimeric form; fragment masses would indicate cleavage), endotoxin (<1 EU/mg), and TAMC/TYMC. For critical mechanistic research applications, a cell-based activity assay (confirmed cytotoxicity in an HDM-2-membrane-expressing cancer cell line such as PANC-1 at the expected IC50, with normal cell sparing control) is the gold-standard quality confirmation beyond chemical purity. All lots are traceable through the batch-specific COA library.
Position PNC-27 as the membrane-HDM-2-targeting poptosis research tool — the only cancer cell-selective peptide that exploits the cancer-specific plasma membrane localization of HDM-2 to form physical transmembrane pores and cause selective tumor cell lysis. Key catalog narratives: (1) “p53-independent killing” makes PNC-27 relevant to research on p53-mutated cancers (which are resistant to most conventional chemotherapy-induced apoptosis); (2) the poptosis mechanism is entirely different from all known resistance mechanisms (Bcl-2 overexpression, caspase deficiency, compound efflux pumps) — positioning it as a compound-resistance bypass research tool; (3) the ex vivo research subjects-derived data (ovarian, pancreatic) is among the most clinically translatable evidence published for any anticancer research peptide. Paired with FOXO4-DRI in the catalog, PNC-27 completes the selective cytotoxic peptide offering: cancer cell necrosis (PNC-27) + senescent cell apoptosis (FOXO4-DRI) — two unique mechanisms from a single longevity/cancer biology research audience.
Key Takeaways
Research Takeaways
- Poptosis mechanism: Peptide-induced transmembrane pore formation → rapid necrosis; p53-independent; caspase-independent; intracellular pathway-independent; resistance mechanism-independent.
- Selectivity target: membrane HDM-2: Aberrantly expressed on cancer cell plasma membranes; absent from normal cell surfaces; PNC-27 active only where surface HDM-2 is present.
- Covalent linkage required: p53 12–26 + penetratin/MRP must be joined as single chimeric peptide; full-length 32-residue integrity is the critical COA quality parameter.
- PNAS 2010 (PMID: 20080680): NMR conformational confirmation; immuno-SEM plasma membrane HDM-2 visualization; TEM pore formation; structural and functional characterization.
- Ex vivo research subjects-derived efficacy: Primary human ovarian and pancreatic cancer specimens; selective cancer cell killing in research subjects tissue.
- No clinical trial published (April 2026): All data in vitro and ex vivo; primarily single research group; independent replication developing.
Business Takeaways
- Only membrane-HDM-2 targeting poptosis compound in YPB catalog — unique mechanism; no overlap with any other catalog compound.
- p53-independent killing = compound resistance bypass narrative; highly relevant in cancer biology research community.
- PNC-27 + FOXO4-DRI = complete selective cytotoxic peptide pair: cancer cell necrosis (PNC-27) + senescent cell apoptosis (FOXO4-DRI).
- Contact YPB for confirmed SKU and pricing for PNC-27.
Ready to add PNC-27 to your research catalog? Book a consultation with the YPB team.
[ypb_studies peptide=”pnc-27″]